Kiromic BioPharma, Inc.
KRBP · OTC
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $557 | $557 |
| Gross Profit | $0 | $0 | -$557 | -$557 |
| % Margin | – | – | – | – |
| R&D Expenses | -$4,531 | $4,228 | $4,135 | $3,022 |
| G&A Expenses | $2,169 | $2,375 | $2,218 | $2,091 |
| SG&A Expenses | $2,169 | $2,375 | $1,661 | $2,091 |
| Sales & Mktg Exp. | $0 | $0 | -$557 | $0 |
| Other Operating Expenses | $8,067 | $0 | $0 | $36 |
| Operating Expenses | $5,705 | $6,603 | $5,796 | $5,113 |
| Operating Income | -$5,705 | -$6,603 | -$6,353 | -$5,113 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$786 | -$832 | -$472 | -$1,035 |
| Pre-Tax Income | -$6,491 | -$7,435 | -$6,825 | -$6,148 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$6,491 | -$7,435 | -$6,911 | -$6,148 |
| % Margin | – | – | – | – |
| EPS | -0.31 | -0.31 | -4.59 | -4.71 |
| % Growth | 0% | 93.2% | 2.5% | – |
| EPS Diluted | -0.31 | -0.31 | -4.59 | -4.71 |
| Weighted Avg Shares Out | 28,519 | 30,968 | 45,182 | 39,136 |
| Weighted Avg Shares Out Dil | 28,519 | 30,968 | 45,182 | 39,136 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $766 | $935 | $957 | $1,071 |
| Depreciation & Amortization | $568 | $552 | $557 | $557 |
| EBITDA | -$5,157 | -$5,948 | -$5,311 | -$4,520 |
| % Margin | – | – | – | – |